黑色素瘤中天然存在的端粒酶特异性CD4 T细胞免疫
研究探讨黑色素瘤患者循环中针对端粒酶的CD4 Th1应答(抗TERT Th1应答)的临床意义。治疗前54.5%(85/156)患者可检测到自发抗TERT Th1应答,其患病率与Breslow厚度>1 mm及AJCC分期≥II呈负相关。该应答与免疫检查点抑制剂治疗的客观缓解、无进展生存和总生存改善相关,提示其可作为血基生物标志物。
要点
- 治疗前54.5%黑色素瘤患者存在自发抗TERT Th1应答。
- 该应答与Breslow厚度>1 mm和AJCC分期≥II呈负相关。
- 该应答与ICI治疗的客观缓解及生存改善相关。
核心结论
- 循环抗TERT Th1应答与黑色素瘤进展呈负相关,并可能是免疫治疗反应的预测因素。
研究设计与样本
- 研究纳入156例黑色素瘤患者,检测治疗前循环抗TERT Th1应答。
主要发现
- 54.5%(85/156)患者治疗前可检测到自发抗TERT Th1应答。
- 该应答与Breslow厚度>1 mm(P = 0.001)和AJCC分期≥II(P = 0.032)呈负相关。
- ICI治疗应答者中86%(18/21)存在治疗前抗TERT Th1应答,非应答者为35%(6/19)(P = 0.001)。
- 该应答与ICI治疗患者无进展生存(P = 0.0008)和总生存(P = 0.012)改善相关。
关键数值与推荐
- 抗TERT Th1应答检测采用外周血循环Th1应答评估。
- 客观缓解与治疗前抗TERT Th1应答相关(应答者86% vs 非应答者35%,P = 0.001)。
临床怎么用
- 抗TERT Th1应答有望作为黑色素瘤ICI治疗的血基预测生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD4 T cells play a key role in anticancer immunity. In this study, we investigate the clinical relevance of circulating CD4 T helper type 1 (Th1) response against telomerase (anti-TERT Th1 response) in patients with melanoma. The spontaneous anti-TERT Th1 response was detected in 54.5% (85/156) of patients with melanoma before treatment. The prevalence of this systemic response was inversely related to Breslow thickness >1 mm and American Joint Committee on Cancer stage ≥II (P = 0.001 and 0.032, respectively). In contrast to patients treated with targeted therapies, the anti-TERT Th1 immunity was associated with an objective response after immune checkpoint inhibitors treatment. Hence, 86% (18/21) of responder patients exhibited pre-existing anti-TERT Th1 versus 35% (6/19) in nonresponders (P = 0.001). This response was also associated with increased progression-free survival and overall survival in patients with melanoma treated with immune checkpoint inhibitors (P = 0.0008 and 0.012, respectively). Collectively, the presence of circulating anti-TERT Th1 response is inversely related to melanoma evolution and appears to be a predictive factor of response to immunotherapy. Our results highlight the interest in telomerase-specific CD4 Th1 response as a promising blood-based biomarker of immune checkpoint inhibitors therapy in melanoma.
引用
- Nardin C, Laheurte C, Puzenat E, et al. Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma. J Invest Dermatol. 2021. PMID: 34352265. doi:10.1016/j.jid.2021.07.160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。